MarketInsightsReports much anticipated examination on Durvalumab market was as of late discharged. It utilizes exploratory systems like subjective and quantitative examination to reveal and introduce information on the objective market. Productive deals procedures have been referenced that would business and increase clients in record time. The details about the competitive landscape presented in the report may also provide an evaluation of the prominent market vendors, their growth profiles, growth strategies, etc., helping stakeholders in quicker decision-making.
“Durvalumab is the generic name for the trade name drug, Imfinzi. In some cases, health care professionals may use the trade name, Imfinzi, when referring to the generic drug name, durvalumab.”
Get Sample Copy of This Report (Free):
“Global Durvalumab market was valued at US$ 10,543.8 million in 2017, and is projected to exhibit a CAGR of 25.4% over the forecast period (2018–2026).”
Durvalumab (trade name Imfinzi) is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 and CD80 (B7.1) molecules. Durvalumab is approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Major industry key players such as : Medimmune (AstraZeneca), …
Durvalumab Market segment by Type, the product can be split into:
Durvalumab Market segment by Application, split into:
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Get Full Detailed Copy of This Report:
Points Covered in The Report:
- The points that are talked over within the report are the major Durvalumab market players that influence the market such as raw material suppliers, manufacturers, equipment suppliers, end users, traders, distributors etc.
- The all-inclusive profile of the companies is specified. The production, price, capacity, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, future strategies, supply, and the technological developments that they are creating are also incorporated within the report. Besides the historical data from 2016 to 2019 and forecast data from 2019 to 2025.
- The growth factors of the Durvalumab market are deeply discussed while the different end users of the market are underlined.
- The report also considers the SWOT analysis of the market. Finally, the report concludes with the opinions of the industry experts
Irfan Tamboli (Head of Sales) – Market Insights Reports
Phone: + 1704 266 3234 | +91-750-707-8687
https://www.linkedin.com/company/13411016/ | https://twitter.com/MIRresearch/
email@example.com | firstname.lastname@example.org